Articles On Dimerix (ASX:DXB)

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high levels...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

It was a big week for our biotech Investment Dimerix (ASX: DXB). Up 50% on huge volumes from news of a US licensing deal that could be worth up to $1BN. DXB is up nearly 1,000% since its 8 cent cap raise in May 2023. What does it actuall...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13...

Highlights: Dateline Resources’ share price surged after political attention on rare earth minerals. Peninsula Energy experiences leadership changes amid halted trading and a downgrade. Biotech companies Telix and Dimerix fa...

Around this time every year, we start to hear a certain saying being muttered around the proverbial ASX investing water coolers. That phrase is 'sell in May and go away'. You might have also heard the antiquated long form of this proverb, w...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.9% to 8,218.5 points. Four ASX shares that are rising more than most today are listed below. Here's w...

Can you believe it has only been one month since US President Donald Trump stood in the Rose Garden of the White House and announced those sweeping and savage 'reciprocal tariffs' that upended global markets? In many ways, it feels like an...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin US markets racheted up another rally, making it eight consecutive positive days. Aft...

The ASX200 closed up 0.24% at 8,145 points. The IT sector surged and was the best performer, up 4%, followed by Real Estate, up 1.6%, and Staples, up 1.4%. Energy shed some of yesterday’s gains and finished down, 1.35%, followed by Ma...

ASX recovers from early dip to post 0.24pc gain Tech stocks surge with sector up 4pc Energy and Materials weigh on gains, down more than 1pc each An after-hours surge in US tech stocks has lit the Aussie tech sector on fire, rocketing up...

Highlights ASX 200 advances as tech sector rallies and large-cap miners ease Andromeda achieves breakthrough in ultra-high purity alumina production Tesla leadership speculation rises amid US economic shifts and trade talks...

Dimerix enters exclusive licence deal with Amicus Therapeutics to commercialise phase III drug candidate DMX-200 in US Deal is for focal segmental glomerulosclerosis and other future indications Dimerix to receive US$30 million upfront pa...

Drug developer Dimerix (ASX: DXB) and US biopharmaceuticals company Amicus Therapeutics have entered into an exclusive US licence agreement for the commercialisation of Dimerix’s lead candidate DMX-200. The drug is under development in a pi...

The ASX has been up 0.2% at around 8,140 points in morning trade. Dimerix (ASX:DMX) has rocketed up around 47% and is the most watched on HotCopper after inking a deal with Nasdaq listed Amicus Therapeutics. The deal will see the commerc...

The share market may be struggling to get into gear on Thursday but that isn't stopping one ASX All Ords stock from racing higher. In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news. Which ASX All Ords sto...

Highlights: DY6 Metals (ASX:DY6) posted strong gallium assay results from its Malawi project, lifting its stock significantly Connected Minerals (ASX:CML) reported uranium exploration results from its Namibian prospect Intel...

ASX uranium stocks have soared after the US administration flagged U3O8 would be included in tariff exemption list Energy sector up more than 2pc, with Small Ords index close behind Utilities, Info Tech, Resources, Real Estate sectors all...

Highlights: The ASX200 index has moved higher, driven by positive momentum across key sectors. Mineral Resources (ASX:MIN) has registered a notable share price increase following its quarterly update. Anson Resources (ASX:AS...

The ASX200 has been up 0.55% at 8,040 points. Mineral Resources (ASX:MIN) has been up more than 12% on release of its quarterly activity report. The company says its commitment to strengthening corporate governance remains unchanged....

Aroa says the real impact from the 10% US tariff imposed on New Zealand goods will be much less than that Quarter time scores show companies are kicking with the wind Dimerix shares enter trading halt ahead of licensing deal   Kiwi wounds...

The FDA has told Telix to do more work on its imaging agent for rare brain cancers But the agency tells Dimerix it can use a surrogate endpoint for its kidney disease drug candidate Emvision opens a second US site to test its stroke detect...

FDA confirms a proteinuria-based endpoint could be basis for full marketing approval of DMX-200 in the US FDA proposal aligns with existing DMX-200 preclinical and clinical efficacy results No additional changes anticipated to the ACTION3...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

Highlights Dimerix Limited has quoted new fully paid ordinary securities on the ASX under code DXB. The company focuses on developing treatments for kidney and respiratory conditions. The listing aims to expand financial cap...

ASX heath sector falls 2.1%, while broader markets also fall 3.8% for the same period as US tariffs spook global markets Regenerative medicine company Orthocell receives US FDA approval for peripheral nerve repair product Remplir  HealthIn...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

Despite a late upturn, the ASX 200 closed 0.38% in the red on Thursday Blame factor 1: Trump and his 25% US auto import tariffs, set to come into play early April Blame factor 2: A Wall Street tech rout, which Trump had a hand in, too   ...

A cabal of ASX drug developers has defied the US gloom The healthcare jury’s out on new FDA head Dr Marty Makary Emvision’s Emu trial takes flight Amid the downbeat narrative about US healthcare policy and cuts to funding agencies, a ‘Mag...

Stockhead joins with IR Department and Morgans for HealthInvest 2025 in Sydney on April 2 Event to highlight some of ASX’s leading up-and-coming health and life sciences companies EMVision, Microba Life Sciences, Orthocell, Lumos Diagnosti...

Highlights: ASX market fluctuations bring varied performances across sectors. Health Care and Telecommunications display resilience, while Utilities and Real Estate show a different trajectory. Several ASX-listed companies p...

 Proteomics launches its diabetic kidney disease assay in Australia Trivarx lines up a sleep-related depression study with US Veterans Affairs The vibes from Trumpland are not great for research-stage biotechs   It’s World Kidney Day, whe...

Profit-making ASX biotechs have been caught up in the market rout During Brain Health Week, let’s not forget about dementia risks Argent looks for Malta site deal While few stocks or sectors have escaped the market correction – or almost...

ASX health stocks fell 0.43% over the past week, while the broader market 2.51% ProMedicus has signed a seven-year, $40 million deal with leading US radiology provider LucidHealth Opthea falls following release of half-year results as it a...

Healthcare leaders stress need for more women in leadership in ASX biotech sector ImpediMed’s female CEO and chair understand challenges for women in sector Dimerix CEO and MD Dr Nina Webster believes workplace flexibility helps women bala...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Dimerix receives upfront payment of ¥300 million (~A$3.2 million) from FUSO Pharmaceutical Industries under licensing deal Company recently inked licensing deal with Japanese company for phase III asset in kidney disease DMX-200 Dimerix el...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese partner   Some healthcare analysts be...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January. Under that deal, FUSO and Dimerix teamed up to develop and commercialise D...

Polynovo and Avita Medical are victims of skittish market behaviour Cyclopharm breathes easier after a good start with US sales Control Bionics raises $2 million to rev up commercialisation   Investor reaction to PolyNovo’s (ASX:PNV) half...

Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy (BIS) device for early detection and prevention of lymph...

Highlights Rapid sector growth offers new prospects for ASX-listed healthcare firms Key players (IPD,DXB,IMR) are enhancing regional presence Rising demand driven by innovation and demographic trends fuels market expansion The healthc...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

  Emyria says its ‘real world’ MDMA trial shows a “sustained improvement” in post-traumatic stress disorder (PTSD) symptoms Argenica says its traumatic brain injury candidate works in rats – and ferrets The biotech sector advanced to recor...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

The ASX200 closed up 1.38% at 8,327 points. Unemployment ticked up to 4%, in line with consensus expectations. The strong jobs data has increased the threshold on what the RBA will need to see in the December quarter inflation numbers fo...

ASX jumps on strong banks and jobs report Zip and Tabcorp surge as markets rally Oil prices soar amid supply risks and cold weather   The ASX flexed its muscles today, up 1.38% on the back of strong bank gains and a bit of global risk-on...

Dimerix Limited (ASX:DXB), a Melbourne-based biopharmaceutical company, has started recruitment for its first paediatric patient for the Phase 3 ACTION3 clinical trial in a major next step for the research. The trial will investigate the...

Pro Medicus signs $33m deal with University of Kentucky Memphasys’ RoXsta system advances antioxidant profiling potential Acrux launches 90-gram Dapsone Gel in US   These are today’s healthcare announcements from the ASX, with major progr...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, inc...